Theseus Pharmaceuticals, Inc.
NASDAQ:THRX
Overview | Financials
Company Name | Theseus Pharmaceuticals, Inc. |
Symbol | THRX |
Currency | USD |
Price | 4.065 |
Market Cap | 181,498,998 |
Dividend Yield | 0% |
52-week-range | 2.05 - 12.37 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Timothy P. Clackson Ph.D. |
Website | https://theseusrx.com |
An error occurred while fetching data.
About Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD